23:10 , Jun 7, 2018 |  BC Week In Review  |  Financial News

Cancer play Xynomic raises series B

Xynomic Pharmaceuticals Inc. (Dover, Del.) raised an undisclosed amount on June 1 in a series B round led by Northern Light Venture Capital, Zhongshan Bison Healthcare Investment and Hakim Unique Internet Co. All of the...
17:41 , Jun 1, 2018 |  BC Extra  |  Financial News

Cancer play Xynomic raises series B

Xynomic Pharmaceuticals Inc. (Dover, Del.) raised an undisclosed amount in a series B round led by Northern Light Venture Capital, Zhongshan Bison Healthcare Investment and Hakim Unique Internet Co. All of the company's existing investors,...
19:51 , Oct 26, 2017 |  BC Innovations  |  Translation in Brief

HATs off to epigenetics

Although the epigenetics field is heating up, most compounds on the market and in development are clustered around the same small set of targets. Now, a team led by AbbVie Inc. (NYSE:ABBV) has uncovered an...
19:48 , Mar 3, 2017 |  BC Week In Review  |  Company News

AbbVie, Xynomic Pharmaceuticals deal

Xynomic received exclusive, worldwide rights to develop and commercialize oncology candidate abexinostat from AbbVie. Xynomic said it plans to start Phase III trials of the histone deacetylase (HDAC) inhibitor in 3Q17. Xynomic declined to disclose...
23:52 , Feb 24, 2017 |  BC Extra  |  Company News

Xynomic licenses AbbVie’s abexinostat

Xynomic Pharmaceuticals Inc. (Cheyenne, Wyo.) said it gained exclusive, worldwide rights to develop and commercialize oncology candidate abexinostat from AbbVie Inc. (NYSE:ABBV). Xynomic said it plans to start Phase III trials of the histone deacetylase...
07:00 , Mar 16, 2015 |  BioCentury  |  Strategy

Bru-te force

AbbVie Inc.'s failed attempt to buy Shire plc last year was based on the expected savings from tax inversion and the opportunity to diversify its pipeline. This time around, the pharma's purchase of Pharmacyclics Inc....
07:00 , Oct 20, 2014 |  BC Week In Review  |  Company News

Pharmacyclics, Servier deal

The companies mutually terminated a 2009 deal granting Servier exclusive, ex-U.S. rights to develop and commercialize abexinostat. The histone deacetylase (HDAC) inhibitor has completed Phase II trials to treat relapsed/refractory follicular lymphoma and mantle...
07:00 , Oct 15, 2012 |  BioCentury  |  Strategy

At home with Servier

Rather than follow in the footsteps of other foundation-backed mid-size European pharmas that have largely concentrated on a single therapeutic area and looked to new markets for growth, Servier has determined its path to sustainability...
07:00 , May 2, 2011 |  BC Week In Review  |  Company News

Pharmacyclics, Servier deal

Pharmacyclics received a $7 million milestone payment from Servier under a 2009 deal granting Servier exclusive, ex-U.S. rights to develop and commercialize PCI-24781/S 78454. The payment was triggered by an undisclosed event. Servier said...
08:00 , Jan 27, 2011 |  BC Innovations  |  Cover Story

HDACs get complex

Cellzome AG has reported a chemical proteomic method for determining the selectivity of HDAC inhibitors. The approach makes it possible, for the first time, to determine the effects of an inhibitor on HDACs as components...